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OBJECTIVE — Exercise tolerance in patients with diabetes is frequently impaired due to
noncardiac disease such as claudication and polyneuropathy. This study assesses the prognostic
value of dobutamine stress myocardial perfusion imaging in patients with diabetes.
RESEARCH DESIGN AND METHODS — A total of 207 consecutive diabetic patients
who were unable to undergo exercise stress testing underwent dobutamine-atropine stress
myocardial perfusion imaging. Follow-up was successful in 206 of 207 (99.5%) patients. A total
of 12 patients underwent early (60 days) revascularization and were excluded from the
analysis. End points during follow-up were hard cardiac events, defined as cardiac death and
nonfatal myocardial infarction.
RESULTS — Abnormal myocardial perfusion was detected in 125 (64%) patients. During
4.1 2.4 years of follow-up, 73 (38%) deaths occurred, 36 (49%) of which were due to cardiac
causes. Nonfatal myocardial infarction occurred in 7 (4%) patients, and 45 (23%) patients
underwent late coronary revascularization. Cardiac death occurred in 2 of 69 (3%) patients with
normal myocardial perfusion and in 34 of 125 (27%) patients with perfusion abnormalities (P
0.0001). A multivariable Cox proportional hazard model demonstrated that, in addition to
clinical and stress test data, an abnormal scan had an incremental prognostic value for prediction
of cardiac death (hazard ratio 7.2, 95% CI 1.7–30). The summed stress score was an important
predictor of cardiac death; the hazard ratio was 1.2 (95% CI 1.07–1.34) per one-unit increment.
CONCLUSIONS — Dobutamine-atropine stress myocardial perfusion imaging provides ad-
ditional prognostic information incremental to clinical data in patients with diabetes who are
unable to undergo exercise stress testing.
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D iabetes is considered a major riskfactor for cardiovascular disease (1–4). Coronary artery disease is a ma-
jor cause of morbidity and mortality in
patients with diabetes. When clinical cor-
onary heart disease develops in patients
with diabetes, the clinical outcome is
worse than in patients with coronary
heart disease without diabetes (5,6). Dia-
betic patients have higher cardiac event
rates, more silent ischemia, and a higher
morbidity after acute myocardial infarc-
tion than nondiabetic patients (7–10).
Myocardial revascularization procedures
in diabetic patients are associated with
higher morbidity and mortality rates than
nondiabetic patients. However, coronary
artery bypass grafting may substantially
improve long-term outcome in selected
diabetic patients (11,12). Therefore, it is
clinically important to determine the risk
of cardiac events in patients with diabetes
in order to select the appropriate manage-
ment strategy.
Several techniques have been pro-
posed for the prognostic stratification of
diabetic patients, such as exercise stress
testing, in conjunction with thallium
scintigraphy or echocardiography (13–
17). However, many diabetic patients are
unable to undergo an exercise stress test
due to the higher prevalence of stroke,
peripheral vascular disease, and neurop-
athy (18 –20). Such patients generally
represent a higher risk population than
patients who are able to undergo exercise
stress testing, and therefore, pharmaco-
logic stress testing may predict a greater
number of cardiac events in these pa-
tients. Dobutamine-atropine stress myo-
cardial perfusion imaging may be a useful
alternative in these high-risk patients
(21,22). However, the value of dobu-
tamine-atropine stress myocardial perfu-
s ion imag ing in the prognos t i c
stratification of diabetic patients has not
been previously studied. The aim of this
study was to assess the incremental prog-
nostic value of dobutamine-atropine
stress myocardial perfusion imaging rela-
tive to clinical data in diabetic patients
who are unable to undergo an exercise
test.
RESEARCH DESIGN AND
METHODS
Patient population
The study population consisted of 207
consecutive patients with diabetes who
were unable to undergo an exercise test
and underwent dobutamine-atropine
stress myocardial perfusion imaging.
These patients were included in an elec-
tronic registry that accumulated in the
course of daily clinical care. The test was
requested for evaluation of myocardial
ischemia in all patients; 91 patients had
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known or suspected coronary artery dis-
ease, 63 had atypical angina, and 53 had
typical angina. Diabetes was defined as a
fasting blood glucose level140 mg/dl or
the need for insulin or oral hypoglycemic
agents. Follow-up was successful in 206
of 207 patients (99.5%). A total of 12 pa-
tients who underwent coronary revascu-
larization within 60 days of the test were
excluded from the analysis. This exclu-
sion was based on previously published
data indicating that referral to coronary
revascularization in the first 60 days after
nuclear testing tends to be based on the
results of the scan and that referral to re-
vascularization 60 days after nuclear
testing tends to be based on worsening of
the patient’s clinical status (23). Data
from the remaining 194 patients are re-
ported. All patients gave informed con-
sent before testing. The medical ethics
committee of the hospital approved the
study protocol.
Clinical data
Before the test, a structured interview was
performed and a clinical history was ob-
tained, including assessment of cardiac
risk factors. Hypertension was defined as
blood pressure 140/90 mmHg or need
for antihypertensive medication. Hyper-
cholesterolemia was defined as total cho-
lesterol level 6.4 mmol/l or need for
lipid-lowering medication.
The type and duration of diabetes, as
well as the presence of diabetic complica-
tions at baseline, including nephropathy,
neuropathy, stroke, retinopathy, and pe-
ripheral atherosclerosis, were assessed by
review of hospital records or contacting
the patient’s treating physician. Nephrop-
athy was defined as a serum creatinine
concentration 250 mol/l, urinary al-
bumin excretion rate in an overnight
specimen 200 g/min on more than
one consecutive occasion, or the need for
dialysis or renal transplantation. Stroke
was defined as a sudden neurologic deficit
that persisted for 24 h and was evi-
denced by a lesion in the expected site of
injury by computed tomography or mag-
netic resonance imaging when available.
Diabetic retinopathy was assessed by ex-
perienced ophthalmologists via ophthal-
moscopy with pupil dilatation and/or
retinal photography. Peripheral athero-
sclerosis was defined as the need for pe-
ripheral bypass surgery or amputation of
at least one digit.
Dobutamine stress protocol
Dobutamine-atropine stress testing was
performed according to a standard proto-
col as previously reported (24). Dobut-
amine was administered intravenously,
starting at a dose of 10g  kg–1  min–1 for
3 min, increasing by 10 g  kg–1  min–1
every 3 min, up to a maximum dose of 40
g  kg–1  min–1. If the test end point was
not reached at a dobutamine dose of 40
g  kg–1  min–1, atropine (1 mg) was
administered intravenously. Blood pres-
sure and heart rate were monitored and
electrocardiography was performed con-
stantly. Test end points included the fol-
lowing: achievement of target heart rate
(85% of maximum age- and sex-predicted
heart rate), horizontal or downsloping
ST-segment depression 2 mm at an in-
terval of 80 ms after the J-point compared
with baseline, ST-segment elevation 1
mm in patients without previous myocar-
dial infarction, severe angina, decrease in
systolic blood pressure 40 mmHg,
blood pressure240/120 mmHg, or sig-
nificant cardiac arrhythmia. Metoprolol
was available for administration to reverse
the adverse effects of dobutamine/
atropine.
Myocardial perfusion imaging
Approximately 1 min before the termina-
tion of the dobutamine-atropine stress
test, an intravenous dose of 370 MBq of
technetium-99m (99mTc)-sestamibi (in
69 patients) or 99mTc-tetrofosmin (in 125
patients) was injected. For resting studies,
370 MBq of the same tracer was injected
at least 24 h after the stress test. Image
acquisition was performed with a com-
mercially available single-photon emis-
sion computed tomography (SPECT)
camera system (Orbiter camera; Siemens,
Iselin, NJ; or Picker Prism 3000XP cam-
era; Picker, Cleveland, OH). For each
study, six oblique (short axis) slices from
the apex to the base and three sagittal
(vertical long axis) slices were defined.
Each of the six short-axis slices was divid-
ed into eight equal segments. The septal
part of the two basal slices was excluded
from analysis because this region corre-
sponds to the fibrous portion of the inter-
ventricular septum and normally exhibits
reduced uptake. Therefore, a total of 47
segments were identified (3 long-axis and
44 short-axis). The interpretation of the
scan was semiquantitatively performed
by visual analysis assisted by the circum-
ferential profiles analysis. Stress and rest
tomographic views were reviewed side-
by-side by two experienced observers
who were unaware of the patients’ clinical
data. In case of disagreement, a majority
decision was achieved by a third observer.
A reversible perfusion defect was defined
as a perfusion defect on stress images that
partially or completely resolved at rest in
2 contiguous segments or slices in the
47-segment model. A fixed perfusion de-
fect was defined as a perfusion defect on
stress images in two or more contiguous
segments or slices that persisted on rest
images in the 47-segment model. An ab-
normal study was considered in the pres-
ence of a fixed and/or reversible perfusion
defect. To assess the severity of perfusion
abnormalities, the left ventricular myo-
cardium was divided into six segments:
anterior, inferior, septal anterior, septal
posterior, posterolateral, and apical. Each
of the six major left ventricular segments
was scored using a four-point scoring sys-
tem (0  normal, 1  slightly reduced,
2moderately reduced, and 3 severe-
ly reduced or absent uptake). The perfu-
sion defect score was derived by the
summation of the score of the six myocar-
dial segments at stress (summed stress
score [SSS]).
Data collection and end points
Follow-up data were obtained by review-
ing hospital records and/or by contacting
Table 1—Baseline characteristics
N 194
Age (years) 61  10
Male sex 116 (60)
Hypertension 110 (57)
Smoking 48 (25)
Hypercholesterolemia 64 (33)
Heart failure 51 (26)
History of myocardial
infarction
82 (42)
History of myocardial
revascularization
52 (27)
-blockers 66 (34)
Calcium channel blockers 102 (53)
Type 1 diabetes 58 (30)
Duration of diabetes (years) 9  10
Complications of diabetes
Nephropathy 37 (19)
Neuropathy 31 (16)
Retinopathy 37 (19)
Peripheral atherosclerosis 34 (18)
Stroke 17 (9)
Data are means  SE or n (%).
Dobutamine-atropine stress imaging
1638 DIABETES CARE, VOLUME 25, NUMBER 9, SEPTEMBER 2002
the patient’s general practitioner. The
date of the last review or consultation was
used to determine follow-up time. The
mean follow-up period was 4.1  2.4
years (range 6 months to 10 years). End
points comprised overall death, cardiac
death, nonfatal myocardial infarction,
and late (60 days) coronary revascular-
ization. Cardiac death was defined as a
death caused by acute myocardial infarc-
tion, significant cardiac arrhythmias, or
refractory congestive heart failure. Sud-
den death occurring without another ex-
planation was included as cardiac death.
Nonfatal myocardial infarction was de-
fined by elevated cardiac enzyme levels
and typical changes on electrocardiogra-
phy.
Statistical analysis
Values were expressed as mean value 
SD or number and were compared using
the Student’s t test or 2 test. Univariate
and multivariate Cox proportional hazard
regression models (BMDP statistical soft-
ware, Los Angeles, CA) were used to iden-
tify independent predictors of late cardiac
events (25). Variables were selected in a
stepwise forward-selection manner with
entry and retention set at a significance
level of 0.05. The risk of a variable was
expressed as a hazard ratio with corre-
sponding 95% CI. The incremental value
of myocardial perfusion scintigraphy over
the clinical variables in the prediction of
events was determined according to two
models. In model I, the variable entered
was the presence of an abnormal scan; in
model II, the SSS was entered. The prob-
ability of survival was calculated using the
Kaplan-Meier method, and survival
curves were compared using the log-rank
test. P 0.05 was considered statistically
significant.
RESULTS
Patient characteristics and
dobutamine stress test
Baseline data from the 194 patients (116
men and 78 women aged 61  10 years)
are summarized in Table 1. During the
dobutamine-atropine stress test, heart
rate increased from 77 17 to 136 17
bpm (P  0.0001), and systolic blood
pressure increased from 144  26 to
158  33 mmHg (P  0.001). The peak
dobutamine dose was 10g  kg–1  min–1
in 5 patients (3%), 20 g  kg–1  min–1 in
24 patients (12%), 30 g  kg–1  min–1 in
35 patients (18%), and 40 g  kg–1 
min–1 in 130 patients (67%). In 78 pa-
tients (40%), atropine was added. Atro-
pine was more frequently administered in
patients using -blocker therapy (41 of
66 patients, 62%) than in those not taking
-blockers (37 of 128, 29%, P 0.0001).
Adverse effects during the test were ven-
tricular tachycardia (10 beats) in 1
patient (0.5%), short ventricular tachy-
cardia (10 beats) in 7 patients (3.6%),
atrial fibrillation in 2 patients (1.0%), se-
vere hypotension (decrease in systolic
blood pressure40 mmHg) in 3 patients
(1.5%), nausea in 11 patients (5.7%), and
headache in 12 patients (6.2%). No pa-
tient experienced a myocardial infarction
or fatal complication. Typical angina oc-
curred in 53 patients (27%), whereas 54
patients (28%) exhibited ST-segment
changes.
Myocardial perfusion images and
follow-up
Abnormal myocardial perfusion was de-
tected in 125 patients (64%). A total of 17
patients (9%) had reversible perfusion de-
Table 2—Predictors of cardiac death
Univariate
Multivariate analysis
Clinical data Model I Model II
Clinical characteristics
Age* 1.07 (1.03–1.12) 1.08 (1.03–1.12) 1.08 (1.03–1.13) 1.08 (1.04–1.13)
Male sex 0.8 (0.4–1.6) NS NS NS
Previous myocardial infarction 1.8 (0.9–3.5) NS NS NS
Hypertension 0.6 (0.3–1.2) NS NS NS
Hypercholesterolemia 1.1 (0.6–2.2) NS NS NS
Smoking 1.2 (0.6–2.5) NS NS NS
Heart failure 3.8 (2.0–7.4) 3.1 (1.6–6.0) 2.5 (1.3–4.9) 2.2 (1.1–4.4)
Type 1 diabetes 1.8 (0.8–3.9) NS NS NS
Duration of diabetes (years)* 1.05 (1.01–1.08) NS NS NS
Diabetic complications
Nephropathy 1.9 (0.8–4.3) NS NS NS
Neuropathy 0.8 (0.3–2.3) NS NS NS
Retinopathy 1.3 (0.5–3.1) NS NS NS
Peripheral atherosclerosis 3.7 (1.6–8.4) 3.2 (1.6–6.5) 3.1 (1.5–6.2) 3.4 (1.7–6.9)
Stroke 2.7 (0.9–7.8) NS NS NS
Stress test results
Typical angina 0.8 (0.3–1.7) — NS NS
ST-segment changes 1.1 (0.5–2.2) — NS NS
Scan parameters
Abnormal scan 9.7 (2.3–40) — 7.2 (1.7–30) —
SSS* 1.21 (1.10–1.34) — — 1.20 (1.07–1.34)
Data are Cox proportional hazard ratio (95% CI). In model I, the variable entered was the presence of an abnormal scan; in model II, the SSS was included. *Per
one-unit increment; —, variable excluded; NS, not statistically significant.
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fects, 61 patients (31%) had fixed defects,
and 47 patients (24%) had fixed plus re-
versible defects. During the follow-up pe-
riod of 4.1 2.4 years, 73 patients (38%)
died; 36 of these patients (19%) died of
cardiac causes. Nonfatal myocardial in-
farction occurred in 15 patients (8%), and
18 patients (9%) underwent late coronary
revascularization (coronary artery bypass
grafting in 6 patients and percutaneous
transluminal coronary angiography in 12
patients). Of the remaining 46 patients
with reversible perfusion defects or fixed
and reversible perfusion defects, most (43
patients) had limited perfusion defects
and received medical treatment; one pa-
tient was accepted for coronary revascu-
larization but died of noncardiac cause
before coronary revascularization, one
patient refused coronary revasculariza-
tion and received medical treatment, and
one patient had normal results of coro-
nary angiography.
Predictive value of clinical data and
test results
During a follow-up period of 4.1  2.4
years, cardiac death occurred in 2 (3%) of
69 patients with normal myocardial per-
fusion and 34 (27%) of 125 patients with
abnormal perfusion (P  0.0001). Uni-
variate and multivariate predictors of car-
diac events are shown in Tables 2 and 3.
Among clinical variables, age, heart fail-
ure, and peripheral atherosclerosis were
independent predictors of cardiac death
and hard cardiac events (cardiac death/
nonfatal infarction). The duration of dia-
betes was a clinical predictor of hard
cardiac events as well. An abnormal scan
provided incremental prognostic infor-
mation over these clinical variables.
Kaplan-Meier survival curves for the end
points cardiac death and cardiac death/
nonfatal infarction are presented in Figs.
1 and 2, respectively. Event-free survival
was significantly better for patients with
normal perfusion than for those with ab-
normal perfusion. In patients with a nor-
mal scan, there was no cardiac mortality
2.5 years after the myocardial perfusion
study. The SSS provided incremental
prognostic information as well (see Tables
2 and 3). Cumulative event rates accord-
ing to the SSS are depicted in Fig. 3. Cu-
mulative event rates increased as a
function of defect extent and severity.
CONCLUSIONS — This study as-
sessed the incremental value of dobu-
tamine-atropine stress myocardial
perfusion imaging in the prediction of
cardiac events in diabetic patients with
limited exercise capacity. Follow-up end
points were cardiac death and nonfatal
myocardial infarction. During the fol-
low-up period of 4.1  2.4 years, 73 pa-
tients (38%) died; 36 of these patients
(27%) died of cardiac causes. Nonfatal
myocardial infarction occurred in 15 pa-
tients (8%), and 18 patients (9%) under-
went late coronary revascularization.
Clinical predictors of cardiac death alone
and hard cardiac events (cardiac death
and myocardial infarction) were age,
heart failure, and peripheral atherosclero-
sis. The duration of diabetes (years) was a
clinical predictor of hard cardiac events as
well. Dobutamine-atropine stress myo-
cardial perfusion imaging provided incre-
mental prognostic information for the
prediction of cardiac death and hard car-
diac events relative to clinical and stress
test data. Cardiac death occurred in 3% of
the patients with normal myocardial per-
fusion and in 27% of the patients with
abnormal perfusion (P  0.0001). The
Table 3—Predictors of hard cardiac events (cardiac death or myocardial infarction)
Univariate
Multivariate analysis
Clinical data Model I Model II
Clinical characteristics
Age* 1.06 (1.03–1.12) 1.06 (1.03–1.11) 1.07 (1.03–1.11) 1.06 (1.03–1.10)
Male sex 0.7 (0.4–1.3) NS NS 0.5 (0.3–0.9)
Previous myocardial infarction 1.6 (0.9–2.9) NS NS NS
Hypertension 0.9 (0.5–1.6) NS NS NS
Hypercholesterolemia 1.0 (0.5–1.9) NS NS NS
Smoking 1.4 (0.7–2.6) NS NS NS
Heart failure 3.2 (1.7–5.9) 2.7 (1.5–5.0) 2.5 (1.4–4.7) 2.1 (1.1–4.0)
Type 1 diabetes 2.0 (0.9–4.2) NS NS NS
Duration of diabetes (years)* 1.04 (1.01–1.08) 1.04 (1.01–1.07) 1.04 (1.01–1.07) 1.04 (1.01–1.07)
Diabetic complications
Nephropathy 1.7 (0.7–3.7) NS NS NS
Neuropathy 0.8 (0.3–2.1) NS NS NS
Retinopathy 1.2 (0.7–1.4) NS NS NS
Peripheral atherosclerosis 3.2 (1.4–7.0) 3.0 (1.6–5.8) 3.3 (1.6–5.9) 3.1 (1.6–6.0)
Stroke NS NS NS
Stress test results
Typical angina 0.8 (0.4–1.7) — NS NS
ST-segment changes 1.1 (0.6–2.0) — NS NS
Scan parameters
Abnormal scan 3.4 (1.4–8.1) — 2.8 (1.2–6.8) —
SSS* 1.16 (1.06–1.27) — — 1.13 (1.02–1.25)
Data are Cox proportional hazard ratio (95% CI). In model I, the variable entered was the presence of an abnormal scan; in model II, the SSS was included. *Per
one-unit increment; —, variable excluded.
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SSS also provided powerful prognostic in-
formation on both end points. These find-
ings demonstrate that the evaluation of
severity of functional abnormalities as a
consequence of coronary artery disease by
dobutamine-atropine stress myocardial
perfusion imaging provides clinically use-
ful information in diabetic patients.
Previous studies
Currently, there are no clinical outcome
data to define the role of dobutamine-
atropine stress myocardial perfusion im-
aging as a prognostic tool in patients with
diabetes (26). Data on the prognostic
value of myocardial perfusion imaging in
diabetic patients are limited. Felsher et al.
(13) demonstrated that exercise planar
thallium imaging was useful for the risk
stratification of 123 diabetic patients.
Four cardiac deaths and eight nonfatal in-
farctions occurred during the follow-up
period of 1.8  0.9 years. Vanzetto et al.
(14) evaluated the prognostic value of ex-
ercise thallium imaging in 158 diabetic
patients. During the follow-up period of
1.9 1.4 years, cardiac death occurred in
8 patients and nonfatal infarction oc-
curred in 14 patients. The authors con-
cluded that inability to exercise was
associated with a high risk of events and
suggested that, for the assessment of
prognosis in these patients, pharmaco-
logic stress myocardial perfusion imaging
be performed. Cohen et al. (15) demon-
strated that abnormal dipyridamole stress
thallium images were important adverse
indictors of long-term prognosis in 101
diabetic patients undergoing peripheral
vascular surgery. Kang et al. (16) evalu-
ated the prognostic value of rest thallium/
stress 99mTc-sestamibi myocardial
perfusion imaging in diabetic patients.
During the follow-up period of 2.0 0.6
years, 50 cardiac deaths and 42 nonfatal
infarctions occurred in 1,080 patients
with diabetes. Most of these patients had
undergone exercise stress testing,
whereas the others had undergone aden-
osine stress testing. As in the present
study, an abnormal scan and the SSS pro-
vided incremental prognostic informa-
tion over clinical data. Recently, Giri et al.
(27) studied 929 diabetic patients after
exercise or vasodilator stress myocardial
perfusion imaging. During a follow-up
period of 2.5  1.5 years, 39 deaths and
41 nonfatal infarctions occurred. The
presence and the extent of abnormal
stress myocardial perfusion imaging inde-
pendently predicted subsequent cardiac
events. Although exercise is the most
physiological stress method and provides
useful prognostic information by study-
ing hemodynamic response and exercise
tolerance, many diabetic patients are un-
able to exercise adequately due to periph-
eral vascular disease, neuropathy, and
degenerative joint disease (18 –20).
Therefore, studies of the prognostic value
of pharmacological stress testing are im-
portant in these patients. Cardiac death
rate in this study is much higher (4.5%)
than in previous studies of diabetic pa-
tients, in which cardiac death rate ranged
between 1.8 and 2.7%. This demonstrates
the importance of noninvasive imaging in
this high-risk population with limited ex-
ercise capacity. Previous studies of the
general population showed that dobu-
tamine-atropine stress myocardial perfu-
sion imaging is an alternative in patients
who are unable to undergo exercise stress
testing (21,22,26), particularly in patients
with relative contraindications to vasodi-
lator stress agents (patients with obstruc-
tive airway disease) or in those who have
ingested caffeine or aminophylline
shortly before stress myocardial perfusion
imaging. The present study is the first to
demonstrate that dobutamine-atropine
stress myocardial perfusion imaging
forms a safe and useful substitute to exer-
Figure 1—Kaplan-Meier survival curves for cardiac death as a function of dobutamine stress
99mTc-sestamibi SPECT results. Event-free survival is much better in patients with normal test
results compared with those with abnormal test results.
Figure 2—Kaplan-Meier survival curves for hard cardiac events (cardiac death/nonfatal infarc-
tion) as a function of dobutamine stress 99mTc-sestamibi SPECT results. A significant difference in
event-free survival exists between patients with normal test results and those in whom test results
are abnormal.
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cise stress imaging in patients with diabe-
tes as well.
In summary, dobutamine-atropine
stress myocardial perfusion imaging is a
clinically useful method for the prognos-
tic stratification of patients with diabetes
who were unable to undergo exercise
stress testing. The test provides incremen-
tal prognostic information relative to clin-
ical parameters. Patients with normal
perfusion have a good prognosis, whereas
patients with an abnormal test are at a
high risk for cardiac events. Both an ab-
normal myocardial perfusion and the SSS
are important determinants of prognosis.
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